Harry J. Leonhardt
2022 - Poseida Therapeutics
In 2022, Harry J. Leonhardt earned a total compensation of $978.3K as General Counsel, Chief Compliance Officer and Corporate Secretary at Poseida Therapeutics, a 32% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,690 |
|---|---|
| Option Awards | $177,109 |
| Salary | $428,833 |
| Stock Awards | $171,000 |
| Other | $12,710 |
| Total | $978,342 |
Leonhardt received $428.8K in salary, accounting for 44% of the total pay in 2022.
Leonhardt also received $188.7K in non-equity incentive plan, $177.1K in option awards, $171K in stock awards and $12.7K in other compensation.
Rankings
In 2022, Harry J. Leonhardt's compensation ranked 3,020th out of 5,505 executives tracked by ExecPay. In other words, Leonhardt earned more than 45.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,020 out of 5,505 | 45th |
Division Manufacturing | 1,693 out of 2,984 | 43rd |
Major group Chemicals And Allied Products | 790 out of 1,339 | 41st |
Industry group Drugs | 736 out of 1,242 | 41st |
Industry Biological Products, Except Diagnostic Substances | 184 out of 287 | 36th |
Source: SEC filing on April 26, 2023.
Leonhardt's colleagues
We found three more compensation records of executives who worked with Harry J. Leonhardt at Poseida Therapeutics in 2022.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019